South Korean artificial intelligence (AI) developer, VUNO Inc., has forged a partnership with Samsung Electronics Co., Ltd., to incorporate its AI-powered chest x-ray diagnostic solution, VUNO Med-Chest X-ray, into Samsung’s mobile digital x-ray system, GM85. The AI integrated x-ray suite is slated to debut in Korea and other major markets around the globe later this year.
Samsung’s GM85 combines a range of technologies, including a quick charging and long-lasting battery, to provide enhanced user-convenience and advanced image quality.
Featuring VUNO’s AI, the integrated mobile x-ray suite will be able to deliver AI results on the spot upon scanning an image while the patient is still in the hospital. This will serve as a useful diagnostic support tool in the emergency room and intensive care units where real time analysis is critical and under other medical environments with limited or no network connections, company officials say.
“I am delighted to partner with Samsung Electronics in embedding our best-of-breed AI solution into their mobile digital x-ray devices. This collaboration will bring us closer to making our market-ready AI applications more accessible across the globe. We will continue to focus on advancing our technology to deliver improved patient outcomes,” says Hyun-jun Kim, co-founder, and CEO of VUNO.
“Incorporating VUNO’s AI technology, we can introduce a more sophisticated mobile X-ray system with AI enabled CAD,” adds Woo-young Jang, Samsung Electronics’ head of the digital radiography business team. “We will continue to extend our partnerships to develop a leadership position in the global x-ray market.”
VUNO Med-Chest X-ray detects and flags suspected chest abnormalities indicative of major pulmonary diseases such as tuberculosis, pneumonia, lung cancer based on five of the most common thoracic findings such as nodule/mass, pneumothorax, interstitial opacity, pleural effusion, and consolidation. The technology has been in full commercial deployment in Korea and Europe after obtaining Ministry of Food and Drug Safety approval and the CE mark in August 2019 and June 2020, respectively.